Aislyn Boran

1.9k total citations · 2 hit papers
27 papers, 983 citations indexed

About

Aislyn Boran is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aislyn Boran has authored 27 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aislyn Boran's work include HER2/EGFR in Cancer Research (7 papers), Computational Drug Discovery Methods (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Aislyn Boran is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Computational Drug Discovery Methods (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Aislyn Boran collaborates with scholars based in United States, France and Switzerland. Aislyn Boran's co-authors include Ravi Iyengar, Patrick Y. Wen, Jan H.M. Schellens, Vivek Subbiah, Zev A. Wainberg, Palanichamy Ilankumaran, Gerald W. Prager, Paul Burgess, Antoîne Italiano and Alexander Stein and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Aislyn Boran

25 papers receiving 975 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

2020 314 citations Vivek Subbiah, Ulrik Lassen et al. The Lancet Oncology profile →
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

2022 183 citations Vivek Subbiah, Robert J. Kreitman et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Aislyn Boran

Since Specialization

Citations

This map shows the geographic impact of Aislyn Boran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aislyn Boran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aislyn Boran more than expected).

Fields of papers citing papers by Aislyn Boran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aislyn Boran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aislyn Boran. The network helps show where Aislyn Boran may publish in the future.

Co-authorship network of co-authors of Aislyn Boran

This figure shows the co-authorship network connecting the top 25 collaborators of Aislyn Boran. A scholar is included among the top collaborators of Aislyn Boran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aislyn Boran. Aislyn Boran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 2025 ·Annals of Oncology ·Cristina Saura, Javier Cortés, Shanu Modi, S.-B. Kim, E.P. Hamilton, (unknown), Ian E. Krop, (unknown), (unknown), S-A. Im, Pia Herbolsheimer, Maha Karnoub, Aislyn Boran, (unknown), Anton Egorov, Fabrice André	0
2	Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03) 2025 ·Clinical Cancer Research ·William Jacot, Seock‐Ah Im, Sherene Loi, Thomas Bachelot, (unknown), Srinivasan Madhusudan, Hiroji Iwata, Giuseppe Curigliano, (unknown), Anton Egorov, Vinit Kumar, Aislyn Boran, Yusuke Kuwahara, Erika Hamilton	2
3	432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04 2024 ·Annals of Oncology ·Naoto T. Ueno, Naoki Niikura, Tetsuro Yamashita, William Jacot, David Cameron, Junji Tsurutani, Joohyuk Sohn, (unknown), María Vidal, Y.H. Park, (unknown), Y.S. Chae, (unknown), Fumitaka Suto, Yusuke Kuwahara, Aislyn Boran, Michihiko Kobayashi, (unknown), (unknown), (unknown)	6
4	Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15 2024 ·Cancer Research ·Shanu Modi, Roberto Salgado, Valentina Guarneri, (unknown), (unknown), (unknown), Aislyn Boran, (unknown), Antonio Llombart‐Cussac	6
5	KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS ^G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC. 2023 ·Journal of Clinical Oncology ·Federico Cappuzzo, Gilberto de Castro, Jin‐Hyoung Kang, Yi‐Long Wu, Odd Terje Brustugun, Parneet Cheema, Taofeek K. Owonikoko, (unknown), Aislyn Boran, (unknown), (unknown), Herbert H. Loong	8
6	Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study breakdown → 2022 ·Annals of Oncology ·Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria, Patrick Y. Wen, C. C. Zielinski, Maria E. Cabanillas, Aislyn Boran, Palanichamy Ilankumaran, (unknown), (unknown), Bhumsuk Keam	183
7	1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma 2021 ·Annals of Oncology ·Caroline Robert, Dirk Schadendorf, Georgina V. Long, Paolo A. Ascierto, Salvatore Intagliata, Friedegund Meier, Astrid A.M. van der Veldt, A. Ribas, Jeffrey S. Weber, Laura Stenson, Nadia Solovieff, (unknown), Aislyn Boran, Jean‐Jacques Grob, Reinhard Dummer	4
8	561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours 2020 ·Annals of Oncology ·Patricia LoRusso, Marwan Fakih, Filip De Vos, J. Thaddeus Beck, Jaime R. Merchan, Geoffrey I. Shapiro, C-C. Lin, Jayesh Desai, Jennifer L. Spratlin, Teresa Cascella, Larissa Sandalic, (unknown), Aislyn Boran, Eduard Gasal, Filip Jankú, Eric Van Cutsem	5
9	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial breakdown → 2020 ·The Lancet Oncology ·Vivek Subbiah, Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg	314
10	Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses 2019 ·Molecular Oncology ·Iman Tavassoly, Yuan Hu, Shan Zhao, Chiara Mariottini, Aislyn Boran, Yibang Chen, Lisa Li, (unknown), Gomathi Jayaraman, Joseph Goldfarb, James M. Gallo, Ravi Iyengar	24
11	Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) 2019 ·Cancer Research ·Caroline Robert, Reinhard Dummer, Ana Arance, Antoni Ribas, Jeffrey S. Weber, Georgina V. Long, John B.A.G. Haanen, Paul C. Nathan, Paolo A. Ascierto, Eduard Gasal, Anthony M. D’Amelio, Severine Bettinger, Aislyn Boran, Dirk Schadendorf	1
12	Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC) 2018 ·Annals of Oncology ·Bhumsuk Keam, Robert J. Kreitman, Zev A. Wainberg, Maria E. Cabanillas, (unknown), Antoîne Italiano, Alexander Stein, Y. Choi, Jan H.M. Schellens, Patrick Y. Wen, C. C. Zielinski, Aislyn Boran, Bijoyesh Mookerjee, (unknown), Fatima Rangwala, Vivek Subbiah	11
13	Neuroprotective Effects of 3,6′-Disinapoyl Sucrose Through Increased BDNF Levels and CREB Phosphorylation via the CaMKII and ERK1/2 Pathway 2014 ·Journal of Molecular Neuroscience ·Yuan Hu, Mingyue Liu, Ping Liu, Xian‐Zhe Dong, Aislyn Boran	43
14	Figure S4 (Related to Figure 4) 2012 ·Aislyn Boran, (unknown), (unknown), Gomathi Jayaraman, (unknown), (unknown), Yibang Chen, Ravi Iyengar	2
15	The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor 2012 ·Biochemical Society Transactions ·Aislyn Boran	2
16	A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor 2012 ·PLoS ONE ·Aislyn Boran, (unknown), (unknown), Gomathi Jayaraman, Shan Zhao, (unknown), Yibang Chen, Ravi Iyengar	19
17	Recovering Protein-Protein and Domain-Domain Interactions from Aggregation of IP-MS Proteomics of Coregulator Complexes 2011 ·PLoS Computational Biology ·Amin R. Mazloom, Ruth Dannenfelser, Neil R. Clark, (unknown), (unknown), Timothy Cardozo, Julia C. Bond, Aislyn Boran, Ravi Iyengar, Anna Malovannaya, Rainer B. Lanz, Avi Ma’ayan	13
18	Identification of new Gβγ interaction sites in adenylyl cyclase 2 2011 ·Cellular Signalling ·Aislyn Boran, Yibang Chen, Ravi Iyengar	9
19	Systems Pharmacology 2010 ·Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine ·Aislyn Boran, Ravi Iyengar	28
20	Quasi One-Dimensional Conductors I 1979 ·Lecture notes in physics ·(unknown), (unknown), Caroline Robert, Aislyn Boran	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact